Level 2, 66 Hunter Street

Sydney NSW 2000

Tel: (61-2) 9300 3344

Fax: (61-2) 9221 6333

E-mail: pnightingale@biotron.com.au

Website: www.biotron.com.au

7 May 2019

The Manager Companies

ASX Limited

20 Bridge Street

SYDNEY NSW 2000

(13 pages by email)

Dear Madam,

NEW ISSUE ANNOUNCEMENT

In accordance with Listing Rule 3.10, I attach an Appendix 3B - New Issue Announcement, Application for Quotation of Additional Securities.

Yours sincerely

Peter J. Nightingale

Company Secretary

pjn9907

Appendix 3B

New issue announcement

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement,

application for quotation of additional securities

and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Biotron Limited

ABN

60 086 399 144

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1+Class of +securities issued or to be issued

2Number of +securities issued or to be issued (if known) or maximum number which may be issued

Fully paid ordinary shares.

150,050 fully paid ordinary shares.

3Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid

+securities, the amount outstanding and due dates for

payment; if +convertible securities, the conversion price and dates for conversion)

Fully paid ordinary shares ranking pari passu with existing ordinary shares.

+ See chapter 19 for defined terms.

04/03/2013

Appendix 3B Page 1

Appendix 3B New issue announcement

4Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?

If the additional +securities do not rank equally, please state:

the date from which they do

the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

5Issue price or consideration

6Purpose of the issue

(If issued as consideration for the acquisition of assets, clearly identify those assets)

6a

Is the entity an +eligible entity

that has obtained security holder

approval under rule 7.1A?

If Yes, complete sections 6b - 6h

in relation to the +securities the

subject of this Appendix 3B, and

comply with section 6i

6b

The date the security holder

resolution under rule 7.1A was

passed

Yes.

$7,502.50.

Exercise of 150,050 12/12/2019 listed options at $0.05 each.

No.

N/A.

6c

Number of +securities issued N/A.

without security holder approval

under rule 7.1

+ See chapter 19 for defined terms.

04/03/2013

Appendix 3B Page 2

Appendix 3B

New issue announcement

6d

Number

of

+securities

issued

N/A.

with security

holder approval

under rule 7.1A

6e

+securities

Number

of

issued

N/A.

with security

holder approval

under rule 7.3, or another

specific security holder approval

(specify date of meeting)

6f

6g

6h

Number of +securities issued under an exception in rule 7.2

If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.

If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

150,050.

N/A.

N/A.

6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A - complete Annexure 1 and release to ASX Market Announcements

7.1- 89,351,916. 7.1A - N/A.

7+Issue dates

7 May 2019.

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

8Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)

Number

+Class

595,679,444

Fully paid ordinary

shares.

106,253,269

12/12/19 5 cent options.

+ See chapter 19 for defined terms.

04/03/2013

Appendix 3B Page 3

Appendix 3B

New issue announcement

Number

+Class

9

Number and

+class

of all

Nil

+securities not quoted on ASX

(including the +securities in

section 2 if applicable)

10

Dividend policy (in the case of a

Remains unchanged.

trust, distribution policy) on the

increased capital (interests)

Part 2 - Pro rata issue

11

Is security

holder

approval

N/A.

required?

12

Is the issue renounceable or non-

N/A.

renounceable?

13

Ratio in which the +securities will

N/A.

be offered

14

+Class of +securities to which the

N/A.

offer relates

15

+Record date to determine

N/A.

entitlements

16Will holdings on different N/A. registers (or subregisters) be aggregated for calculating entitlements?

17Policy for deciding entitlements in relation to fractions

18Names of countries in which the entity has security holders who will not be sent new offer documents

Note: Security holders must be told how their entitlements are to be dealt with.

Cross reference: rule 7.7.

N/A.

N/A.

19Closing date for receipt of N/A. acceptances or renunciations

+See chapter 19 for defined terms.

04/03/2013

Appendix 3B Page 4

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Biotron Limited published this content on 07 May 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 07 May 2019 03:52:01 UTC